Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment.

Chertow DS, Shekhtman L, Lurie Y, Davey RT, Heller T, Dahari H.

Viruses. 2020 Jan 16;12(1). pii: E106. doi: 10.3390/v12010106.

2.

A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics.

Reinharz V, Churkin A, Lewkiewicz S, Dahari H, Barash D.

Bull Math Biol. 2019 Oct;81(10):3675-3721. doi: 10.1007/s11538-019-00644-7. Epub 2019 Jul 23.

PMID:
31338739
3.

Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.

Lhomme S, DebRoy S, Kamar N, Abravanel F, Metsu D, Marion O, Dimeglio C, Cotler SJ, Izopet J, Dahari H.

Viruses. 2019 Jul 9;11(7). pii: E630. doi: 10.3390/v11070630.

4.

Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H.

Vaccine. 2019 May 1;37(19):2608-2616. doi: 10.1016/j.vaccine.2019.02.081. Epub 2019 Apr 5.

PMID:
30962092
5.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

6.

Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Eliav MC, Skorochod Y, Breuer GS, Tur-Kaspa R, Wiener YW, Stern A, Cotler SJ, Dahari H, Lurie Y.

PLoS One. 2019 Feb 7;14(2):e0212252. doi: 10.1371/journal.pone.0212252. eCollection 2019.

7.

A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ.

Antiviral Res. 2019 Mar;163:149-155. doi: 10.1016/j.antiviral.2019.01.017. Epub 2019 Jan 31.

PMID:
30711416
8.

Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Cohen Eliav M, Skorochod Y, Breuer GS, Tur-Kaspa R, Weil Wiener Y, Stern A, Cotler SJ, Dahari H, Lurie Y.

PLoS One. 2019 Jan 15;14(1):e0210173. doi: 10.1371/journal.pone.0210173. eCollection 2019. Erratum in: PLoS One. 2019 Feb 7;14(2):e0212252.

9.

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H.

Liver Int. 2019 May;39(5):826-834. doi: 10.1111/liv.14014. Epub 2018 Dec 28.

PMID:
30499631
10.

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

11.

Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models.

Kumberger P, Durso-Cain K, Uprichard SL, Dahari H, Graw F.

Viruses. 2018 Apr 17;10(4). pii: E200. doi: 10.3390/v10040200.

12.

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K.

Hepatology. 2018 Aug;68(2):473-484. doi: 10.1002/hep.29891. Epub 2018 Jun 6.

13.

Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

Reinharz V, Dahari H, Barash D.

Math Biosci. 2018 Jun;300:1-13. doi: 10.1016/j.mbs.2018.03.011. Epub 2018 Mar 15.

14.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

15.

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K.

PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017.

16.

How to eliminate HCV in people who inject drugs in the USA.

Dahari H, Boodram B.

Lancet Infect Dis. 2018 Feb;18(2):134-135. doi: 10.1016/S1473-3099(17)30678-3. Epub 2017 Nov 15. No abstract available.

17.

A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics.

Reinharz V, Churkin A, Dahari H, Barash D.

Front Appl Math Stat. 2017 Oct;3. pii: 20. doi: 10.3389/fams.2017.00020. Epub 2017 Oct 31.

18.

High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.

Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H.

J Urban Health. 2018 Feb;95(1):71-82. doi: 10.1007/s11524-017-0185-7.

19.

Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H.

Antiviral Res. 2017 Aug;144:281-285. doi: 10.1016/j.antiviral.2017.06.019. Epub 2017 Jun 30.

20.

End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals.

Shteyer E, Dahari H, Gafanovich I, Dery I, Wolf D, Cotler SJ, Lurie Y.

Therap Adv Gastroenterol. 2017 May;10(5):429-430. doi: 10.1177/1756283X17694808. Epub 2017 Feb 1. No abstract available.

Supplemental Content

Loading ...
Support Center